Intra-articular Corticosteroid Injection for Idiopathic Adhesive Capsulitis of the Shoulder

Institutional Review Board, Hospital for Special Surgery

July 31, 2007

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

 

Jennifer L. Solomon, MD

Co-Investigators

 

Jo A. Hannafin, MD, PhD
Scott A. Rodeo, MD
Beth E. Shubin Stein, MD
Lisa R. Callahan, MD
Ronald S. Adler, MD, PhD
Shikha Sethi, MD

Summary

The physicians in this study are seeking a total of one hundred patients to participate over the course of one year.  Following initial diagnosis by the physician, you will be asked to participate in fifteen minute phone call surveys for a total of 6 times during the course of the year.

Inclusion/Exclusion Criteria

If you have had pain or loss of motion in your shoulder lasting nine months or less, one of the investigating physicians may examine you to determine whether you have a condition called adhesive capsulitis.  After this, your physician can further determine your eligibility for participation in this study.

Contact Information

Jennifer Solomon, MD
212.606.1720